Cover storyNPPA Slashes Cancer Drug Prices: ₹696 Becomes ₹73
India’s drug regulator capped mark-ups on 137 cancer drugs, and one brand falls by about 90% from November 9, 2026.
Cover storyIndia’s drug regulator capped mark-ups on 137 cancer drugs, and one brand falls by about 90% from November 9, 2026.

FDA grants Janssen traditional approval for Rybrevant in first-line EGFR exon 20 NSCLC, converting prior accelerated status via RTOR and Project Orbis.

FDA confirms insertional oncogenesis cases linked to Zolgensma, triggering review of labeling and long-term follow-up obligations across AAV gene therapy programs.

FDA approves Lutathera for pediatric GEP-NET patients aged 12+, setting new GMP and post-marketing benchmarks for radiopharmaceutical manufacturers.

FDA approved Ipsen's Onivyde in first-line metastatic pancreatic adenocarcinoma, expanding GMP manufacturing demand for a complex liposomal formulation.
Latest edition
Nov 23
Nov 28From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.

